Drug intelligence / Profile preview

IC47

Development stage: Phase 1
Lead developer: Valneva
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

IC47 is a novel vaccine candidate developed by Valneva Austria GmbH, targeting *Streptococcus pneumoniae*. It is currently undergoing an open-label Phase 1 clinical study to evaluate its safety, tolerability, immunogenicity, and dose response in healthy subjects. The vaccine is administered intramuscularly in varying dose strengths (30 μg or 150 μg) over three doses.

Targets

StkP (Serine/threonine-protein kinase StkP)PsaA (Pneumococcal surface adhesin A)NFKB1 (NF-κB1)

Beyond the preview

Go deeper on IC47.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IC47.

Explore the full profile